A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers
Status:
Completed
Trial end date:
2010-08-06
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the safety and pharmacokinetics of SRT2379 (25,
75, 250, 500, 1000, 2000, and 3000 mg/day [fasted] and 500 mg/day [fed]) in healthy male
volunteers.
The purpose is also to explore the effect of SRT2379 on plasma concentrations of Fibroblast
Growth Factor 21 (FGF21) and to identify other possible biomarkers suitable for future
clinical assessment of oral SIRT1 activators.